Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

4Total
P 2 (4)

Trial Status

Completed3
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT02152995Phase 2Active Not Recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

NCT02973997Phase 2Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

NCT00381641Phase 2Completed

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

NCT02393690Phase 2Completed

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Showing all 4 trials

Research Network

Activity Timeline